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Abstract
Background: Among children, early mortality following highly active antiretroviral therapy (HAART) remains high. It is 
important to define correlates of mortality in order to improve outcome.
Methods: HIV-1-infected children aged 18 months-12 years were followed up at Kenyatta National Hospital, Nairobi 
after initiating NNRTI-based HAART. Cofactors for mortality were determined using multivariate Cox regression models.
Results: Between August 2004 and November 2008, 149 children were initiated on HAART of whom 135 were 
followed for a total of 238 child-years (median 21 months) after HAART initiation. Baseline median CD4% was 6.8% and 
median HIV-1-RNA was 5.98-log10 copies/ml. Twenty children (13.4%) died at a median of 35 days post-HAART 
initiation. Mortality during the entire follow-up period was 8.4 deaths per 100 child-years (46 deaths/100 child-years in 
first 4 months and 1.0 deaths/100 child-years after 4 months post-HAART initiation). On univariate Cox regression, 
baseline hemoglobin (Hb) <9 g/dl, weight-for-height z-score (WHZ) < -2, and WHO clinical stage 4 were associated 
with increased risk of death (Hb <9 g/dl HR 3.00 [95% C.I. 1.21-7.39], p = 0.02, WHZ < -2 HR 3.41 [95% C.I. 1.28-9.08], p = 
0.01, and WHO clinical stage 4, HR 3.08 [1.17-8.12], p = 0.02). On multivariate analysis Hb < 9 g/dl remained predictive of 
mortality after controlling for age, baseline CD4%, WHO clinical stage and weight-for-height z-score (HR 2.95 (95% C.I. 
1.04-8.35) p = 0.04).
Conclusion: High early mortality was observed in this cohort of Kenyan children receiving HAART, and low baseline 
hemoglobin was an independent risk factor for death.
Background
Sub-Saharan Africa carries the highest burden of paediat-
ric HIV-1 with an estimated 1.8 million children < 15
years infected which represents 90% of all children living
with HIV worldwide [1]. In Kenya there are approxi-
mately 150,000 HIV-1 infected children, out of whom
nearly 60,000 are in need of antiretroviral therapy and
about 25,000 are currently accessing treatment [2]. There
is a concerted effort to raise the number of children on
antiretroviral therapy through increased availability of
early infant diagnosis and strengthening provider-initi-
ated counseling and testing in health facilities. As a result,
survival of HIV-1 infected children in Kenya and similar
settings has dramatically improved as more children
access highly active antiretroviral therapy [3-7]. However,
mortality within the first few months of starting antiret-
roviral therapy remains high with various studies report-
ing between 8% and 15% and most deaths attributable to
infections and failure to thrive [3-9]. This level of mortal-
ity is substantially higher than what is observed for chil-
dren initiating HAART in developed nations [10-13].
There is limited but increasing published literature on
predictors of early mortality following initiation of
HAART and few studies have involved African children.
Children with advanced HIV disease manifesting as low
weight-for-height, as well as those with very low CD4%
have been found to be at highest risk of early mortality
following HAART initiation in Cote d'Ivoire, Malawi, and
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Zambia [4,8,9]. In a large Zambian cohort of children fol-
lowed up for a limited period of time, younger age and
low hemoglobin levels were additional factors associated
with higher likelihood of early death following HAART-
initiation [8]. Following the results of the Children with
HIV Early Antiretroviral Therapy (CHER) Trial in which
early treatment reduced early infant mortality by 76%,
international guidelines were modified to recommend
initiation of HAART for infants below 18 months of age
upon HIV diagnosis [14-16]. Initiation of antiretroviral
therapy for older children is still dependent on clinical
and immunologic staging [15]. Ideally, a child would be
diagnosed and treated early, however, in spite of
increased efforts to diagnose children early, some don't
present for care till they are older. Therefore it remains
important to better define factors that impact survival of
such children in local settings with a view to maximize
benefits by addressing any modifiable cofactors. We
describe mortality in a cohort of HIV-1 infected children
receiving antiretroviral therapy who have been followed
up prospectively since 2004.
Methods
The Paediatric Adherence Study is a 5-year prospective
observational study which started enrolling children in
August 2004 as previously described [6]. Children were
drawn from the Paediatric wards and HIV-1 Clinic of the
Kenyatta National Hospital (KNH) in Nairobi Kenya. The
study enrolled children aged 18 months - 12 years who
had advanced clinical and/or immunological HIV disease
(WHO clinical stage 3-4 or WHO clinical stage 2 with
CD4 <15%) and were antiretroviral drug-naïve. After
counseling and informed consent, sociodemographic
information was obtained and a physical examination
performed. Samples were taken for baseline laboratory
investigations including full haemogram, T-cell lympho-
cyte subsets (CD4), plasma HIV-1 RNA, and liver func-
tion tests, and a return appointment given for initiation of
antiretroviral therapy. Children were initiated on a first-
line antiretroviral drug combination recommended by
the Kenya national guidelines which consists of two
nucleoside reverse transcriptase inhibitors (NRTIs) and
one non-nucleoside reverse transcriptase inhibitor
(NNRTI) [16]. Follow-up visits were scheduled after 2
weeks, monthly for the first year, and quarterly thereafter.
At each follow-up visit, children had a physical examina-
tion and information regarding adherence, adverse drug
effects, and intercurrent illness was obtained. Hemato-
logic and biochemical tests for toxicity monitoring and
plasma HIV-1 RNA were performed 3-monthly during
the first year and 6-monthly thereafter, while CD4 counts
were obtained every 6 months. Information on the cause
of death was abstracted from medical records for children
who died in hospital, while for those who died at home,
verbal autopsy was used. The caregiver was invited to the
clinic to give details of the conditions preceding the
child's death and a presumptive diagnosis was reached. In
cases where the caregiver was unable to come to the
research clinic, the study staff paid a home visit to con-
duct the verbal autopsy. Written informed consent was
obtained from all study participants. Verbal assent was
obtained from children between ages 7 and 12 years. This
study received ethical approval from the Institutional
Review Boards of the University of Washington and the
Kenyatta National Hospital.
Statistical methods
Stata version 8 (Stata Corp, College Station Texas) was
used for all analyses. The probability of survival was esti-
mated using the Kaplan-Meier method. Cox proportional
hazards models were used to determine baseline charac-
teristics associated with mortality. Factors found to be
significant predictors of mortality on univariate Cox pro-
portional Hazards model (p value < 0.05) were entered
into a multivariate model. We computed z-scores for
anthropometric measures (weight-for-age, height-for-
age, and weight-for-height) using the Epi-Info (version
3.2, Centers for Disease Control, Atlanta Georgia) using
CDC 2000 reference population. We analyzed weight-for-
height z-score as a categorical variable with a cut off value
of -2 which is the WHO upper limit for children with
moderate protein energy malnutrition [17]. Similarly we
categorized hemoglobin at a cut off value of 9 g/dl, below
which children in low income countries are considered to
have significant iron deficiency anemia [18].
Results
Description of study subjects
One hundred and forty nine children initiated HAART
between August 2004 and December 2006. Baseline char-
acteristics of the children who initiated HAART are
shown in Table 1.
Follow-up and outcomes
Figure 1 provides a summary of follow-up and mortality
among these children. Out of the 149 children who initi-
ated HAART, 135 returned for at least one scheduled fol-
low-up visit two weeks after initiation of treatment. Of
the 14 children who did not complete any clinic follow-
up, one child died 2 days after HAART initiation while for
13 (9%) children there was no follow-up information
available after initiating antiretroviral therapy. By Octo-
ber 2008, median follow-up time on antiretroviral ther-
apy for the 135 who returned to clinic was 21 months
(IQR 6, 33) equivalent to 238 child-years. While on fol-
low-up, six (4%) children were transferred to other medi-
cal facilities on request of caregivers and 20 (13%)
children died. Eleven children (7%) were lost to follow-upWamalwa et al. BMC Pediatrics 2010, 10:33
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Table 1: Baseline characteristics in children who initiated highly active antiretroviral therapy.
Characteristics Number Median (IQR) or N (%)
(N = 149)
Socio-demographic
Age (years) 147 4.9 (2.6, 6.7)
Female 149 74 (50)
Orphaned Lost one parent 149 44 (30)
Lost both parents 149 10 (7)
Clinical
Hospitalization 147 111 (76)
WHO clinical stage 4 145 20 (14)
Anthropometry
Weight for age z-score 142 -2.35 (-3.14, -1.49)
Weight-for-height z-score 133 -1.13 (-1.94, -0.21)
Height for age z-score 141 -2.35 (-3.47, -1.22)
Immunologic
CD4 count cells/μl 145 286 (101, 552)
CD4 cell percent 137 6.8 (3.6, 11.4)
CD4 percent severe immune 
category***
137 122 (89)
Total lymphocyte count cells/mm3 144 3762 (2420, 5788)
Virologic
Log10 HIV-1 RNA copies/ml 127 5.98 (5.44, 6.46)
Hemoglobin g/dl 146 10.2 (9.0, 11.6)
Serum albumin 137 33.0 (28.8, 39.0)
*** Age specific WHO categories for HIV infected children (33)Wamalwa et al. BMC Pediatrics 2010, 10:33
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after completing at least one clinic visit after HAART ini-
tiation.
Mortality
Twenty children died at a median of 35 days post HAART
initiation (IQR 13 - 99 days), of whom 18 (90%) died in
the first 120 days. The mortality rate over the entire fol-
low-up period was 8.4 deaths per 100 child-years (20
deaths over 238 child-years). Mortality in the first 4
months of follow-up was 46 deaths per 100 child-years
(18 deaths over 39 child-years) but this dropped to 1.0
death per 100 child-years between 4 months and 2 years
post-HAART (2 deaths over 199 child-years). The cumu-
lative survival was 95% after 1 month of HAART, 89%
after 3 months and 85% after 6 and 12 months respec-
tively. The cumulative survival after 25 months was 84%
(Figure 2).
Correlates of mortality
On univariate analysis, low baseline hemoglobin level (<9
g/dl), low baseline weight-for-height z-scores < -2, and
WHO stage 4 at baseline were significantly associated
with mortality (Table 2). Trends for association with mor-
tality were also observed for prior hospitalization, base-
line total lymphocyte count, baseline CD4 count, and
serum albumin.
Multivariate analysis
When the significant variables, hemoglobin < 9 g/dl and
baseline weight-for-height z-score < -2, and WHO clini-
cal stage 4 were entered into a single Cox proportional
Hazards model, hemoglobin < 9 g/dl remained predictive
of mortality (HR 2.95 [95% C.I. 1.04, 8.35], p = 0.04).
There were trends of association between weight-for-
height z-score < -2 and mortality (HR 2.48 [95% C.I. 0.87,
7.04], p = 0.09) as well as WHO clinical stage 4 and mor-
tality (HR 3.03 [95% C.I. 0.96-9.55], p = 0.06), Table 2.
Causes of mortality
Nineteen of the 20 (95%) children who died had been
hospitalized at least once since birth and 18 of them were
recruited into the study from the Kenyatta National Hos-
pital paediatric wards. Nine of 20 (45%) children died in
health facilities while 11 (55%) died at home. Of those
dying in health facilities, 8 died in Kenyatta National Hos-
pital while 1 child died in the local district hospital.
Eleven (55%) children had evidence of pneumonia either
from hospital records or information given through ver-
bal autopsy at the time of death. Five children (25%) had
congestive heart failure with ventricular dysfunction sec-
ondary to possible HIV associated cardiac disease. One of
these children had dilated cardiomyopathy on echocar-
diography. Tuberculosis contributed to death in 4 chil-
dren (20%) and one child died from each of the following
conditions: acute diarrhea, Non-Hodgkin's lymphoma,
and anemia. The primary cause of death could not be
established for one child who died at home. Additional
file 1, Table S3 summarizes the characteristics of the 20
children who died after initiation of antiretroviral ther-
apy.
Discussion
In this cohort of HIV-1 infected children who initiated
highly active antiretroviral therapy at advanced immuno-
suppression we observed high early mortality. The first 4
months after HAART initiation were associated with
highest mortality, and children who survived this period
were less likely to die in the subsequent 2 years of follow-
up. In our cohort pre-treatment hemoglobin <9 g/dl,
weight-for-height z-scores < -2, and WHO clinical stage 4
were associated with mortality on univariate analysis.
Only hemoglobin < 9 g/dl remained significantly predic-
tive of mortality on multivariate analysis. However, with
20 events, the power for assessing multiple covariates was
limited and trends remained for weight-for-height z-
score < -2 and WHO clinical stage 4.
Figure 1 Follow-up and retention in the cohort.
Enrolled n = 149 
Followed-up n = 135 
Lost n = 11           
Transfer n = 6
Died n = 19 
Remain in active follow-up     
n = 99 
Did not return        
n = 14 ( 1 died) 
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Table 2: Correlates of mortality among children who initiated HAART.
Univariate




Age ≥3 yrs) 1.30 (0.47-3.62) 0.6 147 99
Sex (female) 0.79 0.33 - 1.91 0.6 149 100
WHO stage 4 3.08 1.17-8.13 0.02 145 97
Hospitalized since birth 7.09 0.95-53.14 0.06 147 97
Weight-for-height z 
score < -2
3.41 1.28-9.08 0.01 142 95
Tuberculosis at 
baseline
1.49 0.62-3.57 0.4 149 100
Lost parent 1.25 0.50-3.13 0.6 149 100
Laboratory
Log HIV-1 RNA 0.80 0.58-1.11 0.2 127 85
CD4 count (per 100 
cells)
0.86 0.73-1.02 0.09 145 97
CD4 percent < 15% 1.74 0.40-7.56 0.5 137 92
Hemoglobin (< 9 g/dl) 3.00 1.21-7.39 0.02 146 98
Total lymphocyte 
count (per 1000)
0.79 0.63 - 1.00 0.05 144 97




2.48 0.87-7.04 0.09 142 95
Hemoglobin (<9 g/dl) 2.95 1.04-8.35 0.04 146 98
WHO stage 4 3.03 0.96-9.55 0.06 147 99Wamalwa et al. BMC Pediatrics 2010, 10:33
http://www.biomedcentral.com/1471-2431/10/33
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Thirteen percent of the children died over the entire
period of follow-up, 12% within the first 4 months of
starting HAART. This falls within the range of mortality
observed in similar African cohorts, but significantly
higher than death rates among HAART-treated children
in industrialized countries [3,4,8-12]. A recent review
comparing mortality in HIV-1 infected children receiving
HAART between resource-rich and resource-limited set-
tings found mean mortality rates of 2.9 vs. 9.0 deaths per
100 person years, respectively, or 4.4% vs. 8.1% with
higher death rates in poor countries [13]. The main dif-
ferences identified between children initiating HAART in
the two settings were higher baseline CD4 levels (24% vs.
11%) and lower baseline viral loads (4.87 log vs. 5.57 log
copies/ml) in resource-rich countries compared to
resource-poor settings, respectively. These differences
indicate that children in resource-rich settings generally
initiated HAART earlier in their illness and suggest that
early initiation of HAART will most likely result in fewer
deaths. The difference in mortality rates could also be due
to the limited supportive care available to children in
resource-poor settings at the most crucial period before
they immune reconstitute to a level that reduces their
vulnerability to potentially fatal opportunistic infections.
Finally, the disparate mortality rates may reflect a differ-
ence in the rates of Immune reconstitution inflammatory
syndrome (IRIS) between the two settings. One child in
our study died from probable TB - IRIS and it is possible
that IRIS contributed to other deaths.
The pattern of mortality we observed is typical of what
has been described in other cohorts of HIV-1 infected
African children receiving HAART [8,9]. The death rate
dropped from a high of 46 deaths per 100 person-years to
1 death per 100 person years, a remarkable fall after the
4-month post-HAART initiation point. The consistent
pattern of high mortality in the first 3-6 months before a
dramatic and sustained decrease in death rate suggests
t h a t  c h i l d r e n  w i t h  s e v e r e  i m m u n e  d e f i c i e n c y  r e q u i r e
some time before the benefits of HAART are fully real-
ized. It appears that with the current approach to therapy
it may be difficult to salvage some children with
extremely advanced HIV and the number of such chil-
dren increases as HAART is initiated much later in the
disease course.
Although there are no data for age-specific mortality
figures for Kenyan children above 5 years, it is notable
that the mortality in our study, (13%) approximates the
current under-5 child mortality in Kenya (128 per 1000
live births) [19]. In contrast, mortality approaching 50%
was reported in an untreated cohort of HIV-1 infected
Kenyan children [20]. Thus the use of HAART has sub-
stantially reduced mortality to rates that are at least as
high as those observed in the general population com-
pared to the pre-HAART period when mortality was
about 3 times higher in HIV infected children.
Our finding of anemia as a predictor of mortality is
consistent with reports from few paediatric and adult
African cohorts [8,9]. It is notable that the levels of ane-
mia in question (Hb < 9 g/dl) are modest and would not
normally lead to rapid clinical deterioration. It is more
likely that anemia is a surrogate marker for advanced HIV
[21,22]. In addition, anemia is a well recognized compo-
nent of severe protein-energy malnutrition which exists
in 5-10% of Kenyan children [23]. We also found a trend
of association between low weight-for-height and mortal-
ity. Growth failure (measured as low weight-for-height or
low weight-for-age) has been found to independently pre-
dict mortality in several studies [8,9,24]. In the context of
our study , in which 89% children were classified in the
severe immune category, weight-for-height z-score < -2
may represent additional nutritional deprivation. The
effect of severe protein energy malnutrition on both
humoral and cell-mediated immunity has been previ-
ously described [25-27]. It is conceivable that children
with both conditions, advanced HIV -1 disease and
severe protein energy malnutrition will have limited
capacity for immune recovery and are especially prone to
life-threatening microbial infections.
Unlike several paediatric studies, we did not demon-
strate a significant association between the baseline
CD4% or viral load and mortality [7,8,28]. This may be
due to the small sample size and generally low CD4
counts, thus limiting power to detect differences between
various CD4 thresholds.
Infectious conditions, specifically pneumonia, contrib-
uted to the greatest number of deaths followed by under-
lying cardiac conditions and tuberculosis. Although
infections remain an important cause of mortality in
HAART-treated children in Western cohorts, the propor-
tion and overall burden of infectious illness is less [12].
Given such a high burden of infectious illness in this
cohort, it is also possible that IRIS played a role in some
of the deaths. A large proportion of the children had
known risk factors for IRIS such as low weight-for-age
and severe immune suppression [29]. Cardiac-related
causes contributed to approximately a quarter of the
deaths in our study. HIV-associated cardiac involvement
presenting as myocarditis, left ventricular dysfunction,
and dilated cardiomoypathy has been described in
patients with advanced disease with low CD4 counts such
as the majority of the children in our cohort [30]. The
mechanisms for cardiac disease include direct effect of
HIV, other cardiotropic viruses, cytokines and opportu-
nistic infections [31,32].
Strengths of our study include long follow-up of chil-
dren starting HAAR T with data on many concurrently
important predictors of mortality (including viral load,Wamalwa et al. BMC Pediatrics 2010, 10:33
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Page 7 of 8
CD4% and nutritional parameters). Limitations of our
study include the relatively small sample size, the lack of
post-mortem studies, and for children who died at home,
reliance on verbal autopsy to determine the cause of
death. This may lead to inaccurate labeling of the cause of
death in such cases. In addition the substantial number of
children lost to follow-up may include children who died
and thereby our study may underestimate mortality.
The importance of our findings relate to building evi-
dence that it may be possible to identify the children at
highest risk of early death following initiation of HAART
in resource-poor settings. Efforts aimed at prompt identi-
fication of HIV infected infants early in the disease course
should be prioritized to enable timely initiation of
HAART in order for children to realize maximal benefits
from expanding treatment programs. It is also important
to investigate targeted interventions that intensify sup-
port for children during the first 4-6 months following
HAART initiation with particular attention given to
those presenting with anemia and low weight-for-height.
Conclusion
Weight-for-height z-score < -2, Hemoglobin <9 g/dl and
WHO stage IV were predictive of mortality on univariate
analysis. Only Hemoglobin <9 g/dl at baseline remained
independently predictive of mortality. Besides efforts to
initiate HAART earlier in the course of illness, HIV
i n f e c t e d  c h i l d r e n  p r e s e n t i n g  w i t h  a n e m i a  a n d  s e v e r e
wasting should be especially prioritized for care post-
HAART initiation. Targeted research on the role of nutri-




The authors declare that they have no competing interests.
Authors' contributions
All authors read and approved the final manuscript. DW was the lead author
who led the design and conduct of the study as well as manuscript develop-
ment. EO provided clinical expertise and epidemiological input in manuscript
development. CF provided epidemiological support for manuscript develop-
ment. BAR provided guidance on study design and led statistical analysis. DMN
gave input on clinical and epidemiological aspects of the study and manu-
script development. II provided clinical care of the children in study and gave
input on clinical aspects of manuscript development. B provided statistical
support while GJS provided mentorship in the overall design and epidemio-
logical aspects of the study and manuscript development.
Acknowledgements
Research was funded by the NIH Fogarty International Center, NIH grants D43 
TW000007, R01 TW007632 and Puget Sound Partners for Global Health 
Research and Technology Project Award # 26145. D. Wamalwa was a scholar in 
the AIDS International Training and Research Program supported by the NIH 
Fogarty International Center grant D43 TW00007 and subsequently a recipient 
of the Global Research Initiative Program, Social Science (R01 TW007632). C. 
Farquhar was supported by NICHD K23 HD41879. G. John-Stewart was an Eliza-
beth Glaser Paediatric AIDS Foundation (EGPAF) Scientist and was supported 
by a NICHD K24 Grant and D. Mbori-Ngacha had an EGPAF International Lead-
ership Award. Antiretroviral drugs were provided by the US Presidents Emer-
gency Program for AIDS Relief (PEPFAR).
Author Details
1Department of Paediatrics, University of Nairobi, Box 19676 Nairobi 00202, 
Kenya, 2Department of Epidemiology University of Washington, 325 Ninth 
Avenue, Box 359909, Seattle, 98104, USA, 3Department of Medicine University 
of Washington, 325 Ninth Avenue, Box 359909, Seattle, 98104, USA, 
4Department of Biostatistics University of Washington, Box 325 Ninth Avenue, 
359909, Seattle, 98104, USA and 5Kenyatta National Hospital, Ngong Road, 
Nairobi, 00202, Kenya
References
1. UNAIDS 2008 Report on the Global AIDS Epidemic   [http://
www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008]
2. National AIDS and STI Control Programme, Ministry of Health Kenya   
[http://www.aidskenya.org]
3. Reddi A, Leeper SC, Grobler AC, et al.: Preliminary outcomes of a 
paediatric highly active antiretroviral therapy cohort from KwaZulu-
Natal, South Africa.  BMC Pediatr 2007, 7:13.
4. Rouet P, Fassinou P, Inwoley A, et al.: Long-term survival and immune-
virologic response of African HIV-1 infected children to highly active 
antiretroviral therapy regimens.  AIDS 2006, 20(18):2315-9.
5. Song R, Jelagat J, Dzombo D, et al.: Efficacy of highly active antiretroviral 
therapy in HIV-1 infected children in Kenya.  Pedaitrics 2007, 
120(4):e856-61.
6. Wamalwa D, Farquhar C, Obimbo E, et al.: Early response to highly active 
antiretroviral therapies among HIV-1-infected Kenyan children.  J 
Acquir Immune Defic Syndr 2007, 45:311-317.
7. Puthanakit T, Oberdorfer A, Akarathum N, et al.: Efficacy of highly active 
antiretroviral therapy in HIV-infected children participating in 
Thailand's National Access to Antiretroviral Program.  Clin Infect Dis 
2005, 41(1):100-7.
8. Bolton-Moore C, Mubiana-Mbewe M, Cantrell J, et al.: Clinical outcomes 
and CD4 response in children receiving antiretroviral therapy at 
primary health care facilities in Zambia.  JAMA 2007, 298(16):1888-1899.
9. Bong Chin-Nam, Yu Kwong-Leung J, Chiang H, et al.: Risk factors for early 
mortality in children on adult fixed-dose combination antiretroviral 
therapy in a central hospital in Malawi.  AIDS 2007, 21:1805-18.
10. Gortmaker SL, Hughes M, Cervia J, et al.: Effect of combination therapy 
including protease inhibitors on mortality among children and 
adolescents infected with HIV-1.  N Engl J Med 2001, 345:1522-8.
11. Gibb DM, Duong T, Tookey PA, et al.: Decline in mortality, AIDS and 
hospital admissions in perinatally HIV-1 infected children in the United 
Kingdom and Ireland.  BMJ 2003, 327:1019-24.
12. Viani R, Araneta M, Deville J, et al.: Decrease in hospitalization and 
mortality rates among children with perinatally acquired HIV type 1 
infection receiving highly active antiretroviral therapy.  Clin Infect Dis 
2004, 39:725-31.
13. Peacock-Villada E, Richardson B, John-Stewart G: Paediatric HAART 
treatment outcomes: A comparison of developing and developed 
countries.  16th Conference on Retroviruses and Opportunistic Infections 
(CROI 2009), Montreal, Canada, February 8-11 2009 . Abstract 875
14. Violari A, Cotton M, Gibb D, et al.: Early Antiretroviral Therapy and 
Mortality among HIV-1 infected Infants.  N Engl J Med 2008, 359:2233-44.
15. World Health Organization: Guidelines for the use of Antiretroviral 
Agents in Paediatrics.  World Health Organization Geneva; 2009. 
16. National AIDS and STI Control program (NASCOP): Guideline for 
antiretroviral therapy in Kenya.  Third edition. Ministry of health, 
Government of Kenya, Nairobi Kenya; 2005. 
Additional file 1 Table S3. Characteristics of children who died after 
initiation of highly active antiretroviral therapy. This table contains a 
detailed description of all the children who died following initiation of anti-
retroviral therapy including their ages at enrolment, baseline CD4 and 
plasma HIV-1 RNA, presenting diagnosis, duration on antiretroviral therapy 
and suspected cause of death.
Received: 10 December 2009 Accepted: 18 May 2010 
Published: 18 May 2010
This article is available from: http://www.biomedcentral.com/1471-2431/10/33 © 2010 Wamalwa et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Pediatrics 2010, 10:33Wamalwa et al. BMC Pediatrics 2010, 10:33
http://www.biomedcentral.com/1471-2431/10/33
Page 8 of 8
17. World Health Organization: Management of severe malnutrition: a 
manual for physicians and other senior health workers.  World Health 
Organization Geneva; 1999. 
18. Lutter CK: Iron deficiency in young children in low income countries 
and new approaches for its prevention, a review.  J Nutri 2008, 
138:2523-2528.
19. Monitoring the Situation of Children and Women, Statistics by 
Country, Kenya   [http://www.unicef.org/infobycountry/
kenya_statistics.html]
20. Obimbo E, Mbori-Ngacha DA, Ochieng J, et al.: Predictors of early 
mortality in a cohort of Human Immunodeficiency Virus Type-1 
infected African children.  Pediatr Infect Dis J 2004, 23:536-543.
21. Moore RD: Human immunodeficiency virus infection, Anemia and 
survival.  Clin Infect Dis 1999, 29:44-49.
22. Consolini R, Benviclli W, Legino A, et al.: Pre HAART follow-up study of the 
hematological manifestation in children with prenatal HIV infection, 
suggestions for reclassification of clinical disease.  Italian register for HIV 
infection in children Pediatr Hematol Oncol 2007, 29:376-383.
23. Kenya Demographic Health Survey.  Central Bureau of Statistics, Nairobi 
Kenya; 2003. 
24. Marazzi M, Liotta G, Germano P, et al.: Excessive Early Mortality in the 
First Year of Treatment in HIV Type 1-Infected Patients Initiating 
Antiretroviral Therapy in Resource-Limited Settings.  AIDS Res and Hum 
Retro 2008, 24:555-60.
25. McMurray DN: Cell-mediated immunity in nutritional deficiency.  Prog 
Food Nutr Sci 1984, 8(3-4):193-228.
26. Najera O, Gonzalez , Cortes E, et al.: Effector T lymphocytes in well-
nourished and malnourished infected children.  Clin Exp Immunol 2007, 
148(3):501-6.
27. Najera O, Najera O, Gonzalez , Toledo , et al.: Flow cytometry study of 
lymphocytes in malnourished and well-nourished children with 
bacterial infections.  Clin Diag Lab Immunol 2004, 11(3):577-80.
28. Fassinou P, Elenga N, Rouet F, et al.: Highly active antiretroviral therapies 
among HIV-1-infected children in Abidjan, Cote d'Ivoire.  AIDS 2004, 
18:1905-13.
29. Smith K, Kuhn L, Coovadia , et al.: Immune reconstitution inflammatory 
syndrome among HIV-infected South African infants initiating 
antiretroviral therapy.  AIDS 2009, 23:1097-1107.
30. Pairoj R, Wongpraparut , Jacobs LE, et al.: Cardiac Manifestations of 
Acquired Immunodeficiency Syndrome.  Arch Intern Med 2000, 
160:602-608.
31. Dau B, Holodniy M: The relationship between HIV infection and 
Cardiovascular disease.  Curr Cardiol Rev 2008, 4:203-218.
32. Martinez E, Larrousse M, Gatell J: Cardiovascular disease and HIV 
infection: host, virus, or drugs?  Curr Opin Infect Dis 2009, 22:28-34.
33. World Health Organization, Geneva Switzerland: Antiretroviral therapy of 
HIV infection in infants and children in resource-limited settings: 
towards universal access. Recommendations for a public health 
approach.  World Health Organization, Geneva; 2006. 
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2431/10/33/prepub
doi: 10.1186/1471-2431-10-33
Cite this article as: Wamalwa et al., Predictors of mortality in HIV-1 infected 
children on antiretroviral therapy in Kenya: a prospective cohort BMC Pediat-
rics 2010, 10:33